Published in Virology on July 15, 1981
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Variable major proteins of Borrellia hermsii. J Exp Med (1982) 5.62
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood (2011) 2.22
Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody. Infect Immun (1984) 2.07
Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol (1984) 1.93
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol (2008) 1.74
p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A (1998) 1.73
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candida albicans. Infect Immun (1986) 1.70
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol (1994) 1.64
A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci U S A (1989) 1.64
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. J Exp Med (1986) 1.50
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50
Mutational analysis of N-linked glycosylation sites of Friend murine leukemia virus envelope protein. J Virol (1991) 1.48
Horizontal transmission of murine retroviruses. J Virol (1987) 1.41
Analyses of gonococcal H8 antigen. Surface location, inter- and intrastrain electrophoretic heterogeneity, and unusual two-dimensional electrophoretic characteristics. J Exp Med (1985) 1.40
Infectious entry of murine retroviruses into mouse cells: evidence of a postadsorption step inhibited by acidic pH. J Virol (1985) 1.37
Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol (1993) 1.36
Tissue-specific replication of Friend and Moloney murine leukemia viruses in infected mice. J Virol (1987) 1.36
Sequences in the U5-gag-pol region influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J Virol (1990) 1.34
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Site-directed deletions of Abelson murine leukemia virus define 3' sequences essential for transformation and lethality. J Virol (1983) 1.33
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection. J Virol (2001) 1.22
Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol (1986) 1.21
Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20
Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo. J Virol (1997) 1.20
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration. J Virol (1986) 1.18
Class II polytropic murine leukemia viruses (MuLVs) of AKR/J mice: possible role in the generation of class I oncogenic polytropic MuLVs. J Virol (1987) 1.17
Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol (1995) 1.14
Identification of two forms of an endogenous murine retroviral env gene linked to the Rmcf locus. J Virol (1987) 1.13
bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation. Mol Cell Biol (1990) 1.12
Murine retrovirus-induced spongiform encephalomyelopathy: host and viral factors which determine the length of the incubation period. J Virol (1992) 1.12
Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest (1986) 1.11
Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med (1988) 1.11
Monoclonal antibodies that inhibit attachment of group B coxsackieviruses. J Virol (1983) 1.09
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J Virol (2002) 1.05
A membrane-associated, carbohydrate-modified form of the v-abl protein that cannot be phosphorylated in vivo or in vitro. J Virol (1984) 1.05
Friend virus utilizes the BMP4-dependent stress erythropoiesis pathway to induce erythroleukemia. J Virol (2007) 1.04
p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol Cell Biol (1999) 1.03
MCF-specific murine monoclonal antibodies made against AKR-247 MCF virus recognize a unique determinant associated with the gp70-p-15(E) complex. J Virol (1982) 1.03
Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection. J Virol (2001) 1.01
Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01
The neuroinvasiveness of a murine retrovirus is influenced by a dileucine-containing sequence in the cytoplasmic tail of glycosylated Gag. J Virol (1998) 1.01
Immune sera and antiglycoprotein monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies viruses. J Virol (1987) 0.99
A multistep process of leukemogenesis in Moloney murine leukemia virus-infected mice that is modulated by retroviral pseudotyping and interference. J Virol (1996) 0.99
Protection against retroviral diseases after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses. J Virol (1993) 0.98
Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J Virol (1990) 0.98
A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J Virol (1995) 0.97
Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene (2009) 0.97
Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties. J Virol (1999) 0.95
Pathogenesis of arteritis of SL/Ni mice. Possible lytic effect of anti-gp70 antibodies on vascular smooth muscle cells. J Exp Med (1987) 0.94
Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation. J Virol (1996) 0.93
Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. J Virol (1991) 0.92
Identification of a unique erythroleukemia-associated retroviral gp70 expressed during early stages of normal erythroid differentiation. J Exp Med (1984) 0.90
Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain. J Virol (2001) 0.90
Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro. J Virol (1993) 0.90
Monoclonal antibodies against baboon endogenous virus and against host cell antigens. J Virol (1982) 0.90
Increase of retroviral infection in vitro by the binding of antiretroviral antibodies. J Virol (1986) 0.89
Sequences responsible for the distinctive hemolytic potentials of Friend and Moloney murine leukemia viruses are dispersed but confined to the psi-gag-PR region. J Virol (1993) 0.89
Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. J Virol (2003) 0.89
The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J Virol (2003) 0.89
Humoral immunity in the Friend retrovirus infection model. Immunol Res (2013) 0.87
Identification of a 36,000-molecular weight, gag-related phosphoprotein in lymphoma cells transformed by radiation leukemia virus. J Exp Med (1984) 0.85
Recombinant hydrophilic region of murine retroviral protein p15E inhibits stimulated T-lymphocyte proliferation. Proc Natl Acad Sci U S A (1987) 0.85
Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus. Proc Natl Acad Sci U S A (1992) 0.85
The carboxyl terminus of v-Abl protein can augment SH2 domain function. J Virol (2000) 0.84
Macrophages are the first thymic cells to express polytropic retrovirus in AKR mouse leukemogenesis. J Virol (1991) 0.84
Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis. J Virol (2005) 0.84
In vivo interactions of ecotropic and polytropic murine leukemia viruses in mixed retrovirus infections. J Virol (2006) 0.84
Interference established in mice by infection with Friend murine leukemia virus. J Virol (1992) 0.83
Characterization of a novel murine retrovirus mixture that facilitates hematopoiesis. J Virol (2002) 0.83
Susceptibility of nude mice carrying the Fv-4 gene to Friend murine leukemia virus infection. J Virol (1997) 0.82
Profound amplification of pathogenic murine polytropic retrovirus release from coinfected cells. J Virol (2012) 0.81
Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS One (2009) 0.81
Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus. J Virol (2008) 0.80
The absence of Msh2 alters abelson virus pre-B-cell transformation by influencing p53 mutation. Mol Cell Biol (2000) 0.80
Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells. J Virol (2004) 0.80
An interleukin-1 beta-encoding retrovirus exhibits enhanced replication in vivo. J Virol (2014) 0.79
Moloney leukemia virus immortalizes B lymphocytes in vitro. J Virol (1991) 0.77
Decreased virus population diversity in p53-null mice infected with weakly oncogenic Abelson virus. J Virol (2005) 0.76
Identification of genetic determinants responsible for the rapid immunosuppressive activity and the low leukemogenic potential of a variant of Friend leukemia virus, FIS-2. J Virol (1998) 0.76
SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus. J Virol (2011) 0.75
Lipopolysaccharide restores anti-Candida albicans growth inhibition activity of polymorphonuclear neutrophils from retrovirus-immunosuppressed mice. Infect Immun (1993) 0.75
Spontaneous priming for anti-viral envelope cytotoxic T lymphocytes in mice transgenic for a murine leukaemia virus envelope gene (Fv4). Immunology (1997) 0.75
Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus. J Virol Methods (2014) 0.75
Genetic regulation of long-term nonprogression in E-55+ murine leukemia virus infection in mice. J Virol (1999) 0.75
A small cosmid for efficient cloning of large DNA fragments. Gene (1980) 22.61
Cosmids: a type of plasmid gene-cloning vector that is packageable in vitro in bacteriophage lambda heads. Proc Natl Acad Sci U S A (1978) 16.33
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst (1997) 4.60
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
School-based programs to reduce sexual risk behaviors: a review of effectiveness. Public Health Rep (1994) 4.50
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Plasmids useable as gene-cloning vectors in an in vitro packaging by coliphage lambda: "cosmids". Gene (1978) 3.66
Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Activation of a transposable element in the germ line but not the soma of Caenorhabditis elegans. Nature (1987) 3.00
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Gonadotrophin stimulation test ovarian function. Br Med J (1968) 2.99
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Organization and function of an accident flying squad. Br Med J (1966) 2.88
Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol (1990) 2.88
Instability of palindromic DNA in Escherichia coli. Cold Spring Harb Symp Quant Biol (1981) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Escherichia coli plasmids packageable in vitro in lambda bacteriophage particles. Methods Enzymol (1979) 2.71
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
Fertility and ageing. Hum Reprod Update (2005) 2.68
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol (2001) 2.59
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Sequence interruptions in enterobacterial repeated elements retain their ability to encode well-folded RNA secondary structures. Mol Microbiol (1997) 2.33
Free ribosomal DNA molecules from Tetrahymena pyriformis GL are giant palindromes. J Mol Biol (1976) 2.33
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Precise and nearly-precise excision of the symmetrical inverted repeats of Tn5; common features of recA-independent deletion events in Escherichia coli. Gene (1983) 2.21
Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet (1995) 2.19
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
Safer choices: reducing teen pregnancy, HIV, and STDs. Public Health Rep (2001) 2.07
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Communications. "In vitro" cell reactions in delayed hypersensitivity. J Immunol (1969) 2.03
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Human peroxisomal 3-oxoacyl-coenzyme A thiolase deficiency. Proc Natl Acad Sci U S A (1987) 1.98
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
A case of asthma. Br Med J (1976) 1.95
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol (1996) 1.94
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
Relationship between chromosome replication and F'lac episome replication in Escherichia coli. J Mol Biol (1973) 1.89
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. J Infect Dis (1991) 1.85
Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology (1993) 1.83
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Envelopment of human cytomegalovirus occurs by budding into Golgi-derived vacuole compartments positive for gB, Rab 3, trans-golgi network 46, and mannosidase II. J Virol (2003) 1.80
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79